Rathika Krishnasamy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rathika Krishnasamy has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
- Carmel Mary Hawley
Australasian Kidney Trials Network (AKTN), The University of Queensland, Brisbane, Queensland, Australia
11 shared publications - David Wayne Johnson
Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia
7 shared publications - Nicholas A. Gray
Sunshine Coast University Hospital, Birtinya, Queensland, Australia
4 shared publications Tony Stanton
Department of Cardiology, Sunshine Coast University Hospital, Birtinya, Australia
4 shared publications- Elaine Mary Pascoe
Australasian Kidney Trials Network, Centre for Health Services Research, University of Queensland, Brisbane, Queensland, Australia
3 shared publications - Jeff Scott Coombes
School of Human Movement and Nutrition Sciences, The University of Queensland, St Lucia, Queensland, Australia
3 shared publications
Latest Publications
- 10 November 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
A Dip before Benefit?
Was not provided for this article.
- 10 November 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
A Dip before Benefit?
Was not provided for this article.
- Open Access
- 28 July 2026
- Published by Elsevier in Kidney International
- Vol. 110 (4) , 812-828
International Society of Nephrology International Expert Forum: Exploring the Nexus of Cardiovascular-Kidney-Metabolic Health
- 28 July 2026
- Published by Elsevier in Kidney International
- Vol. 110 (4) , 812-828
Open AccessInternational Society of Nephrology International Expert Forum: Exploring the Nexus of Cardiovascular-Kidney-Metabolic Health
- 15 July 2026
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 22 (9) , 591-592
Oscars’ inclusion standards for kidney trials
- 15 July 2026
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 22 (9) , 591-592
Oscars’ inclusion standards for kidney trials
- Open Access
- 16 September 2025
- Published by Wiley in Nephrology
- Vol. 30 (9) , e70119
CARI Guidelines Commentary on the KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases
Aim: The KDIGO 2021 Glomerular Disease Guidelines provide updated recommendations on the management of glomerular diseases (GD), with substantial advances made in diagnosis, treatment, and improvement of outcomes for people with GD. Methods: The Caring for Australians and New Zealanders with kidney Impairment (CARI) Guidelines commentary contextualises the updated guidelines for the Australian and New Zealand setting. Results: Kidney biopsy remains central to diagnosis, with validated scoring systems available. However, genetic testing for suspected monogenic kidney disease is now accessible in Australia, enabling earlier diagnosis and management, particularly in situations where a kidney biopsy is considered high risk or contraindicated. The guideline emphasises timed urine collections for protein excretion over spot tests and we suggest the use of the CKiD u25 eGFR equation for people under 25. For IgA nephropathy (IgAN) and IgA vasculitis (IgAV), emerging therapies such as targeted‐release budesonide and sparsentan demonstrate promise but await approval and public subsidy in our region. For membranous nephropathy, the guideline highlights the differences in adult and paediatric management. In nephrotic syndrome, tacrolimus is used as first‐line therapy and rituximab as a second‐line agent for steroid‐dependent or frequently relapsing disease. Minimal change disease recommendations include glucocorticoid tapering after remission, while focal segmental glomerulosclerosis incorporates genetic classifications and advocates for next‐generation sequencing. Conclusion: Our commentary underscores the need for increased participation in clinical trials to validate regional applicability and improve long‐term outcomes for people with GD in Australia and New Zealand. Clinical trials of new medications have led to more treatment options that are awaiting approval.
- 16 September 2025
- Published by Wiley in Nephrology
- Vol. 30 (9) , e70119
Open AccessCARI Guidelines Commentary on the KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases
Aim: The KDIGO 2021 Glomerular Disease Guidelines provide updated recommendations on the management of glomerular diseases (GD), with substantial advances made in diagnosis, treatment, and improvement of outcomes for people with GD. Methods: The Caring for Australians and New Zealanders with kidney Impairment (CARI) Guidelines commentary contextualises the updated guidelines for the Australian and New Zealand setting. Results: Kidney biopsy remains central to diagnosis, with validated scoring systems available. However, genetic testing for suspected monogenic kidney disease is now accessible in Australia, enabling earlier diagnosis and management, particularly in situations where a kidney biopsy is considered high risk or contraindicated. The guideline emphasises timed urine collections for protein excretion over spot tests and we suggest the use of the CKiD u25 eGFR equation for people under 25. For IgA nephropathy (IgAN) and IgA vasculitis (IgAV), emerging therapies such as targeted‐release budesonide and sparsentan demonstrate promise but await approval and public subsidy in our region. For membranous nephropathy, the guideline highlights the differences in adult and paediatric management. In nephrotic syndrome, tacrolimus is used as first‐line therapy and rituximab as a second‐line agent for steroid‐dependent or frequently relapsing disease. Minimal change disease recommendations include glucocorticoid tapering after remission, while focal segmental glomerulosclerosis incorporates genetic classifications and advocates for next‐generation sequencing. Conclusion: Our commentary underscores the need for increased participation in clinical trials to validate regional applicability and improve long‐term outcomes for people with GD in Australia and New Zealand. Clinical trials of new medications have led to more treatment options that are awaiting approval.
- 26 August 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (1) , 147-149
Adaptive Designs for Clinical Trials in Nephrology
An abstract is unavailable. This article is available as a PDF only.
- 26 August 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (1) , 147-149
Adaptive Designs for Clinical Trials in Nephrology
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 28 July 2023
- Published by Elsevier in Kidney International Reports
- Vol. 8 (9) , 1711-1713
Vitamin K in CKD: A Game-Changer or By-Stander
- 28 July 2023
- Published by Elsevier in Kidney International Reports
- Vol. 8 (9) , 1711-1713
Open AccessVitamin K in CKD: A Game-Changer or By-Stander
- Open Access
Synbiotics Easing Renal Failure by Improving Gut Microbiology II (SYNERGY II): A Feasibility Randomized Controlled Trial
Synbiotics have emerged as a therapeutic strategy for modulating the gut microbiome and targeting novel cardiovascular risk factors, including uremic toxins indoxyl sulfate (IS) and p-cresyl sulfate (PCS). This study aims to evaluate the feasibility of a trial of long-term synbiotic supplementation in adults with stage 3–4 chronic kidney disease (CKD). Adult participants with CKD and estimated glomerular filtration rate (eGFR) of 15–60 mL/min/1.73 m2) were recruited between April 2017 and August 2018 to a feasibility, double-blind, placebo-controlled, randomized trial of synbiotic therapy or matched identical placebo for 12 months. The primary outcomes were recruitment and retention rates as well as acceptability of the intervention. Secondary outcomes were treatment adherence and dietary intake. Exploratory outcomes were evaluation of the cardiovascular structure and function, serum IS and PCS, stool microbiota profile, kidney function, blood pressure, and lipid profile. Of 166 potentially eligible patients, 68 (41%) were recruited into the trial (synbiotic n = 35, placebo n = 33). Synbiotic and placebo groups had acceptable and comparable 12-month retention rates (80% versus 85%, respectively, p = 0.60). Synbiotic supplementation altered the stool microbiome with an enrichment of Bifidobacterium and Blautia spp., resulting in a 3.14 mL/min/1.73 m2 (95% confidence interval (CI), −6.23 to −0.06 mL/min/1.73 m2, p < 0.01) reduction in eGFR and a 20.8 µmol/L (95% CI, 2.97 to 38.5 µmol/L, p < 0.01) increase in serum creatinine concentration. No between-group differences were observed in any of the other secondary or exploratory outcomes. Long-term synbiotic supplementation was feasible and acceptable to patients with CKD, and it modified the gastrointestinal microbiome. However, the reduction in kidney function with synbiotics warrants further investigation.
Open AccessSynbiotics Easing Renal Failure by Improving Gut Microbiology II (SYNERGY II): A Feasibility Randomized Controlled Trial
Synbiotics have emerged as a therapeutic strategy for modulating the gut microbiome and targeting novel cardiovascular risk factors, including uremic toxins indoxyl sulfate (IS) and p-cresyl sulfate (PCS). This study aims to evaluate the feasibility of a trial of long-term synbiotic supplementation in adults with stage 3–4 chronic kidney disease (CKD). Adult participants with CKD and estimated glomerular filtration rate (eGFR) of 15–60 mL/min/1.73 m2) were recruited between April 2017 and August 2018 to a feasibility, double-blind, placebo-controlled, randomized trial of synbiotic therapy or matched identical placebo for 12 months. The primary outcomes were recruitment and retention rates as well as acceptability of the intervention. Secondary outcomes were treatment adherence and dietary intake. Exploratory outcomes were evaluation of the cardiovascular structure and function, serum IS and PCS, stool microbiota profile, kidney function, blood pressure, and lipid profile. Of 166 potentially eligible patients, 68 (41%) were recruited into the trial (synbiotic n = 35, placebo n = 33). Synbiotic and placebo groups had acceptable and comparable 12-month retention rates (80% versus 85%, respectively, p = 0.60). Synbiotic supplementation altered the stool microbiome with an enrichment of Bifidobacterium and Blautia spp., resulting in a 3.14 mL/min/1.73 m2 (95% confidence interval (CI), −6.23 to −0.06 mL/min/1.73 m2, p < 0.01) reduction in eGFR and a 20.8 µmol/L (95% CI, 2.97 to 38.5 µmol/L, p < 0.01) increase in serum creatinine concentration. No between-group differences were observed in any of the other secondary or exploratory outcomes. Long-term synbiotic supplementation was feasible and acceptable to patients with CKD, and it modified the gastrointestinal microbiome. However, the reduction in kidney function with synbiotics warrants further investigation.
- 22 January 2020
- Published by S. Karger AG in Blood Purification
- Vol. 49 (4) , 468-478
A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study
Background: A new class of dialysis membrane, the mid cut-off (MCO) dialyzer, has been developed to improve the clearance of uremic toxins in hemodialysis (HD). The a tRial Evaluating Mid cut-Off Value membrane clearance of Albumin and Light chains in HemoDialysis patients (REMOVAL-HD) study aimed to determine if regular use of MCO dialyzer was safe and specifically did not result in a significant loss of albumin. Methods: This investigator initiated, crossover, longitudinal, device study was conducted across 9 centers in Australia and New Zealand (n = 89). Participants had a 4-week wash-in with high-flux HD, followed by 24-week intervention with MCO HD and a subsequent 4-week wash-out with high-flux HD. The primary outcome was change in serum albumin between weeks 4 and 28. Secondary outcomes included trends in serum albumin, changes in kappa- and lambda-free light chains (FLC), 6-min walk test (6MWT), malnutrition inflammation score (MIS), restless legs score and quality of life. Results: Participants had a mean age of 66 ± 14 years, 62% were men, 45% were anuric, and 51% had diabetes. There was no reduction in serum albumin following treatment with MCO HD (mean reduction –0.7 g/L, 95% CI –1.5 to 0.1). A sustained, unexplained reduction in serum albumin (>25%) was not observed in any participant. A reduction in FLC was observed 2 weeks into MCO HD (lambda-FLC: Δ –9.1 mg/L, 95% CI –14.4 to –3.7; kappa-FLC: Δ –5.7 mg/L, 95% CI –9.8 to –1.6) and was sustained for the rest of the study intervention. Both FLC increased after the cessation of MCO use. There was no improvement in restless legs symptoms, quality of life, 6MWT or MIS scores. Conclusions: Regular HD using the MCO dialyzer did not result in a significant fall in serum albumin. There were no effects on quality of life, functional status or nutrition. Trial Registration: Australian New Zealand Clinical Trials Registry Number (ANZCTRN) 12616000804482.
- 22 January 2020
- Published by S. Karger AG in Blood Purification
- Vol. 49 (4) , 468-478
A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study
Background: A new class of dialysis membrane, the mid cut-off (MCO) dialyzer, has been developed to improve the clearance of uremic toxins in hemodialysis (HD). The a tRial Evaluating Mid cut-Off Value membrane clearance of Albumin and Light chains in HemoDialysis patients (REMOVAL-HD) study aimed to determine if regular use of MCO dialyzer was safe and specifically did not result in a significant loss of albumin. Methods: This investigator initiated, crossover, longitudinal, device study was conducted across 9 centers in Australia and New Zealand (n = 89). Participants had a 4-week wash-in with high-flux HD, followed by 24-week intervention with MCO HD and a subsequent 4-week wash-out with high-flux HD. The primary outcome was change in serum albumin between weeks 4 and 28. Secondary outcomes included trends in serum albumin, changes in kappa- and lambda-free light chains (FLC), 6-min walk test (6MWT), malnutrition inflammation score (MIS), restless legs score and quality of life. Results: Participants had a mean age of 66 ± 14 years, 62% were men, 45% were anuric, and 51% had diabetes. There was no reduction in serum albumin following treatment with MCO HD (mean reduction –0.7 g/L, 95% CI –1.5 to 0.1). A sustained, unexplained reduction in serum albumin (>25%) was not observed in any participant. A reduction in FLC was observed 2 weeks into MCO HD (lambda-FLC: Δ –9.1 mg/L, 95% CI –14.4 to –3.7; kappa-FLC: Δ –5.7 mg/L, 95% CI –9.8 to –1.6) and was sustained for the rest of the study intervention. Both FLC increased after the cessation of MCO use. There was no improvement in restless legs symptoms, quality of life, 6MWT or MIS scores. Conclusions: Regular HD using the MCO dialyzer did not result in a significant fall in serum albumin. There were no effects on quality of life, functional status or nutrition. Trial Registration: Australian New Zealand Clinical Trials Registry Number (ANZCTRN) 12616000804482.
- 1 October 2018
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 31 (10) , 1127-1136
Diastolic Dysfunction Assessed Using Contemporary Guidelines and Prognosis Following Myocardial Infarction
- 1 October 2018
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 31 (10) , 1127-1136
Diastolic Dysfunction Assessed Using Contemporary Guidelines and Prognosis Following Myocardial Infarction
- 25 April 2018
- Published by Wiley in Nephrology
- Vol. 23 (5) , 453-460
Low socio‐economic status adversely effects dialysis survival in Australia
Aim: Low socio‐economic status (SES) is associated with increased incidence of end‐stage kidney disease and in the USA, poorer dialysis survival. All Australians have access to a universal healthcare system.Methods: The study included all non‐indigenous adult Australians registered with the Australia and New Zealand Dialysis and Transplant Registry who commenced dialysis between 2003 and 2013. SES at dialysis start was classified into quartiles of advantaged through to disadvantaged using Australian Bureau of Statistics socio‐economic indexes for areas. The primary outcome was survival assessed using a competing risk regression model with renal transplantation as a competing risk. There was a significant interaction between age and SES, and hence, age‐stratified survival analyses were performed.Results: A total 20 810 commenced dialysis during the study period. Mortality for the most advantaged quartile was 102.4/1000 person–years (95% confidence interval (CI) 98.0–106.9) compared with 110.7/1000 person–years (95% CI 105.8–115.7) in the disadvantaged quartile. In adjusted analysis, dialysis survival, compared with quartile 1 (advantaged), was inferior in quartile 3 (sub‐hazard ratio 1.10, 95% CI 1.03–1.17) and the disadvantaged quartile (sub‐hazard ratio 1.09, 85% CI 1.02–1.16) and was significantly modified by age. This disparity in survival outcome between the different SES quartiles was only observed in younger patients but was attenuated in the older ones following an age‐stratified analysis.Conclusions: In Australia, low SES has an adverse effect on dialysis patient survival despite universal healthcare. This effect is mainly among younger patients where SES may have a greater proportional impact than co‐morbidities.
- 25 April 2018
- Published by Wiley in Nephrology
- Vol. 23 (5) , 453-460
Low socio‐economic status adversely effects dialysis survival in Australia
Aim: Low socio‐economic status (SES) is associated with increased incidence of end‐stage kidney disease and in the USA, poorer dialysis survival. All Australians have access to a universal healthcare system.Methods: The study included all non‐indigenous adult Australians registered with the Australia and New Zealand Dialysis and Transplant Registry who commenced dialysis between 2003 and 2013. SES at dialysis start was classified into quartiles of advantaged through to disadvantaged using Australian Bureau of Statistics socio‐economic indexes for areas. The primary outcome was survival assessed using a competing risk regression model with renal transplantation as a competing risk. There was a significant interaction between age and SES, and hence, age‐stratified survival analyses were performed.Results: A total 20 810 commenced dialysis during the study period. Mortality for the most advantaged quartile was 102.4/1000 person–years (95% confidence interval (CI) 98.0–106.9) compared with 110.7/1000 person–years (95% CI 105.8–115.7) in the disadvantaged quartile. In adjusted analysis, dialysis survival, compared with quartile 1 (advantaged), was inferior in quartile 3 (sub‐hazard ratio 1.10, 95% CI 1.03–1.17) and the disadvantaged quartile (sub‐hazard ratio 1.09, 85% CI 1.02–1.16) and was significantly modified by age. This disparity in survival outcome between the different SES quartiles was only observed in younger patients but was attenuated in the older ones following an age‐stratified analysis.Conclusions: In Australia, low SES has an adverse effect on dialysis patient survival despite universal healthcare. This effect is mainly among younger patients where SES may have a greater proportional impact than co‐morbidities.